Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business UpdatePRNewsWire • 08/04/22
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid WithdrawalPRNewsWire • 05/19/22
Mind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety DisordersPRNewsWire • 05/11/22
MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business UpdatePRNewsWire • 05/09/22
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH SymposiumPRNewsWire • 04/14/22
Mind Medicine (MindMed) Inc. (MNMD) CEO Rob Barrow on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/28/22